Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod-induced inflammation and complement activation in healthy volunteers
NL-OMON51378Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jan 2022
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imiquimod, sponsored by Centre for Human Drug Research. Primary endpoints: Cytokines and immune cells in skin biopsies, Local complement factors in skin biopsies and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
imiquimod
Beyond the preview
Go deeper on NL-OMON51378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51378.